Recommended Topic Related To:

Tretten

"Regular blood transfusions prevent recurrent blockage of brain blood vessels, a serious neurological side effect that occurs in one third of children with sickle cell anemia, according to a study funded by the National Institutes of Health. The f"...

Tretten

TRETTEN, Coagulation Factor XIII A-Subunit
(catridecacog) Coagulation Factor XIII A-Subunit (Recombinant)

DRUG DESCRIPTION

TRETTEN, Coagulation Factor XIII A-Subunit (Recombinant), is a recombinant human factor XIII-A2 homodimer composed of two factor XIII (FXIII) A-subunits. The FXIII A-subunit is a 731 amino acid chain with an acetylated N-terminal serine. When FXIII is activated by thrombin, a 37 amino acid peptide is cleaved from the N-terminus of the A-subunit.

TRETTEN is manufactured as an intracellular, soluble protein in yeast (Saccharomyces cerevisiae) production strain containing the episomal expression vector, pD16. It is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography. No human or animal derived products are used in the manufacturing process.

TRETTEN is supplied as a sterile, white lyophilized powder in a single use vial. Table 1 and Table 2 list the vial content of reconstituted TRETTEN and the diluent, respectively.

Table 1 : Content of Reconstituted TRETTEN*

Content Per Vial* Function
Coagulation Factor XIII A-Subunit (Recombinant) 2000 - 3125 IU Active substance
Sodium Chloride 8.70 mg Stabilizer
Sucrose 174.0 mg Stabilizer
Polysorbate 20 0.30 mg Surfactant
L-Histidine 9.30 mg Buffer
* Values are given per 3 mL reconstituted TRETTEN.

Table 2 : Content of Diluent for Reconstitution of TRETTEN

Content Per Vial Function
Sterile Water for Injection 3.2 mL Diluent

After reconstitution with 3.2 mL sterile water for injection, each vial contains 667-1042 IU/mL of recombinant coagulation factor XIII A-subunit. The reconstituted solution has a pH of approximately 8.0. The formulation contains no preservative and must only be administered intravenously.

Last reviewed on RxList: 3/21/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.